Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival
Nd multivariable analysis higher DC-SCRIPT levels were associated with a favorable outcome for both the entire cohort and patients with lymph node-negative (LNN) disease that did not receive adjuvant therapy (DFS, MFS and OS; all, P
Noma in situ; DC-SCRIPT, dendritic cell-specific transcript gene; ERBB2+, HER2neu-positive; ESR, estrogen receptor gene; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; PGR, progesterone receptor gene; pT1, small tumor without lymphatic/vascular invasion.(Spearman's rho = 0.87; P
Inter-quartile after normalization on the reference gene set. cP for Spearman rank correlation test. dP for Mann-Whitney U test. eP for Kruskal-Wallis test, including a Wilcoxon-type test for trend when appropriate. fWith quantitative polymerase chain reaction cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, respectively, and for ESR2 at the median level of 0.005 (mRNA levels rela
Of DC-SCRIPT are associated with reduced tumor aggressiveness. The association is particularly strong for small tumors with high ESR1 or low ESR2 mRNA levels or both. Finally, although DC-SCRIPT negatively regulates ESR1 and PGR activity, DC-SCRIPT levels measured in theSieuwerts et al. Breast Cancer Research 2010, 12:R103 http://breast-cancer-research.com/content/12/6/RPage 9 ofprimary tumors are
Lpropane-1,3-diamine. Acknowledgements We especially thank the patients and surgeons, pathologists, and internists for their assistance in collecting tumor tissues and patients' clinical follow-up data. We thank Joan Bolt, Marion Meijer, Mieke Timmermans, Anita Trapman, and Wendy van der Smissen for their excellent technical support. This work was financially supported by VICI grant 918-66-615 (aw
Lpropane-1,3-diamine. Acknowledgements We especially thank the patients and surgeons, pathologists, and internists for their assistance in collecting tumor tissues and patients' clinical follow-up data. We thank Joan Bolt, Marion Meijer, Mieke Timmermans, Anita Trapman, and Wendy van der Smissen for their excellent technical support. This work was financially supported by VICI grant 918-66-615 (aw
Stic marker. The data that emerged from this study thus validate the hypothesis that DCSCRIPT is associated with good prognosis in early disease and support the idea that DC-SCRIPT acts as a tumor suppressor in breast cancer progression [7]. Because of the size of this cohort and the biological function of DC-SCRIPT as a nuclear receptor co-regulator, we were able to include additional subgroup an